Using blood tests to screen for Alzheimer's disease
Blood-based Biomarkers for Early Alzheimer's Disease Screening
This study is testing if certain blood tests can help find Alzheimer's disease early in people who have it, those with mild memory problems, and those who are healthy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 180 (estimated) |
| Ages | 50 Years and up |
| Sex | All |
| Sponsor | Peking University First Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06477484 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness of specific blood biomarkers in identifying Alzheimer's disease and related cognitive impairments. It focuses on biomarkers such as Aβ40, Aβ42, P-Tau181, P-Tau217, GFAP, and NfL in various patient groups, including those diagnosed with Alzheimer's, those with mild cognitive impairment, and cognitively normal individuals. The study seeks to establish a reliable model for early detection of Alzheimer's disease through blood testing.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 50 and older who have Alzheimer's disease, mild cognitive impairment, or are cognitively normal.
Not a fit: Patients with other disorders causing cognitive impairment or those unable to cooperate with cognitive assessments may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier and more accurate screening for Alzheimer's disease, allowing for timely interventions.
How similar studies have performed: Other studies have shown promise in using blood biomarkers for Alzheimer's screening, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 50 years; * AD (meets the 2011 NIA-AA AD diagnostic criteria), or MCI (meets the 2004 Peterson MCI diagnostic criteria), or cognitively normal subjects; * Signed informed consent form. Exclusion Criteria: * The presence of other disorders that can cause cognitive impairment; * Unable to cooperate with the completion of cognitive assessment; * Refusal to draw blood.
Where this trial is running
Beijing, Beijing Municipality
- Peking University First Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Chen Zhang
- Email: chenzizm@126.com
- Phone: 86+83572462
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.